EMA publishes overview of ICH GCP E6 R3 Annex 2 comments
What does this mean for Good Clinical Practice training and clinical trial innovation
A new development has emerged for clinical research. Everyone in the industry should be aware of an important date. On May 20, 2025, the European Medicines Agency (EMA) released a 47-page document. This document includes comments on ICH E6 R3 GCP Annex 2. It provides an overview of the feedback received on ICH E6 R3 GCP. In my opinion, this document is full of valuable insights.
This is not another regulatory document that will be collecting dust on someone’s desk. It offers a glimpse into the perceptions of people in the industry regarding the future of clinical trials. And quite frankly, the truth is that the feedback is far more open and thought-provoking than most people expected
What makes this document special?
It paints a rather unique picture in the world of over-regulated documents: constructive analyses, lived experiences from an often overlooked diverse constituency, and rich discussions, sometimes long-winded. We’re referring to contributions from all corners of the world including pharmaceutical companies, clinical and academic researchers, advocacy groups, and all therein, including regulation and policy experts.
However, this is what many people have not realized concerning the feedback process. This collection is different from standard consultations. Instead of shallow and routine comments, it offers deep and thorough insights. It thoughtfully engages with the key factors changing clinical research.
The three pillars of modern clinical trials
As mentioned in the GCP considerations in Annex 2, there are examples of trials. These trials include decentralized, pragmatic, and real-world data elements. These are not simply phrases—they feature disruptive innovations in the conduct of clinical research.
1. Decentralized Clinical Trials (DCTs)
The pandemic guaranteed hybrid trials would not be a fleeting phenomenon. Although the regulatory side of the discussion lags. Both sides of the debate display a fascinating tension between innovation and oversight.
Some stakeholders commented on the greater flexibility that DCTs afford. Others noted challenges around data security and information technology control systems. Finding the right balance is critical, and comments on the topic promise a lot of guidance.
Key insights from the comments:
- New validation methods are needed for remote monitoring protocols
- Patient-reported outcomes require more rigorous verification
- Technology platforms must comply with the defined GCP requisite(s)
- Investigator oversight mechanisms need redefinition
2. Pragmatic Clinical Trials
Pragmatic trials serve as a bridge between the two extremes of controlled research and the clinical setting. The comments reveal significant discussion about how far “pragmatic” can go while maintaining scientific rigor.
Traditional randomized controlled trials excel at internal validity but often struggle with external validity. Pragmatic trials flip this equation, prioritizing real-world applicability. The regulatory implications are enormous.
Stakeholder concerns highlighted:
- Balancing scientific rigor with practical flexibility
- Clarifying acceptable levels of protocol deviation
- Maintaining patient safety in less controlled environments
- Ensuring regulatory acceptance across jurisdictions
3. Real-World data integration
One of the most debated topics in the comments is the integration of real-world data (RWD). With electronic health records, wearable tech, and administrative databases, we have incredible opportunities to generate clinical evidence. However, these advancements also bring significant challenges. The comments reveal a split in the industry regarding data quality, standardization, and regulatory acceptance.
Impact on Good Clinical Practice Certification programs
ICH GCP Certification Updates: Addressing Decentralized and Pragmatic Trials
The 47-page overview is not just a list of bullet points. It tells a story about the future of clinical research and the challenges we face.
Site Selection Strategy
Traditional site selection criteria may become obsolete in the Annex 2 world. When trials incorporate decentralized elements, the definition of a “site” becomes fluid. Some comments suggested new competency frameworks for site evaluation.
Good Clinical Practice certification requirements for Quality Management Systems
Quality management systems built for traditional trials struggle with hybrid and decentralized designs. The comments point out areas where sponsors must change their methods. This means updates are needed for Good Clinical Practice training:
- Risk-based monitoring in virtual environments
- Source data verification for patient-generated data
- CAPA (Corrective and Preventive Action) processes for technology failures
- Training programs for distributed research teams
Currently, ICH GCP certification programs inadequately address these operational realities, creating a significant skills gap in the workforce.
ICH GCP Training needs for Patient-Centricity implementation
When we talk about patient-focused methods in clinical trials, “patient-centric” is a popular term in healthcare. However, comments from Annex 2 show the real challenges of using these patient-focused trial designs in practice. This disconnect is creating a pressing need for specialized ICH GCP training modules.
Here are some practical considerations that call for improved training:
- Strategies to reduce the burden on patients without sacrificing data quality
- Accessibility measures for a wide range of patient populations
- Cultural awareness in global trial designs
- Health literacy needs for digital platforms
Traditional Good Clinical Practice training programs often do not cover patient engagement strategies well. This leads to challenges in implementing these strategies across the industry.
Data Integrity in the new paradigm
One of the more technical parts of the comments dives into the data integrity requirements for modern trial designs. This isn’t just an IT issue, it’s a core question about what really counts as reliable clinical evidence.
Source Data definition evolution
Traditional Good Clinical Practice (GCP) offers a pretty straightforward definition of source data. However, when patients start generating data at home with their personal devices, things get a bit tricky. The comments highlight ongoing discussions about:
- Who owns the data, and who is responsible for it
- How to identify and verify source data
- Backup and recovery plans for distributed systems
- Documentation of the chain of custody for digital assets
Monitoring paradigm shifts
Risk-based monitoring was meant to change the game for clinical trials. Yet, the comments indicate it hasn’t quite lived up to its expectations. In decentralized and pragmatic trials, the old-school monitoring methods are proving to be even less effective.
New monitoring strategies being discussed include:
- Predictive analytics for risk identification
- Real-time data review and exception reporting
- Patient-reported monitoring feedback
- Automated quality assurance systems
Regulatory science evolution
The comments shed light on a crucial aspect of regulatory science. Traditional regulatory frameworks were built around standardized protocols and predictable data streams. However, modern trials are producing a variety of evidence that calls for different evaluation methods.
Evidence standards flexibility
Some stakeholders are pushing for more adaptable evidence standards that acknowledge the unique value of various trial designs. On the flip side, others caution against compromising scientific rigor in the name of efficiency.
This discussion goes beyond ICH E6. It raises important questions about how regulatory agencies look at clinical evidence and make approval decisions.
Real-World evidence integration
The FDA and EMA have published guidance on real-world evidence, but the Annex 2 comments reveal significant implementation challenges. Integration isn’t just about data collection; it’s about analytical methods, interpretation frameworks, and regulatory decision-making processes
Geographic and Cultural Considerations
One often overlooked part of feedback is the geographic and cultural factors in modern trial designs. Decentralized trials can reach people all over the world. However, they also show cultural barriers that can limit participation.
Digital divide implications
Not all patients have equal access to digital technologies. The comments highlight concerns about inadvertently excluding certain populations from clinical trials through technology requirements.
Specific issues raised:
- Disparities in technology access between rural and urban areas
- Challenges in digital literacy that vary by age
- Socioeconomic barriers that affect technology adoption
- Cultural perspectives on data sharing and privacy
Regulatory framework variations
The ICH wants to create harmony, but feedback shows that the way these rules are applied can vary a lot by region. What may be effective in one area might not translate well to another, posing challenges for global trial designs.
Implementation timeline and practical implications
Annex 2 will provide guidance on practical and decentralized clinical trials. It will also cover trials that use real-world data. ICH plans to finalize it by 2025. However, the actual implementation will take quite a bit longer.
Immediate actions for sponsors
Based on the comment themes, sponsors should consider several immediate actions:
- Technology infrastructure assessment
- Take a close look at current systems to ensure they align with Annex 2
- Spot any gaps in data management capabilities
- Evaluate cybersecurity measures and privacy protections
- Prepare for challenges in system integration
- Training program development
- Refresh GCP training materials to reflect modern trial designs
- Create competency frameworks tailored for distributed teams
- Create patient-facing educational resources
- Set up protocols for technology support
- Quality system evolution
- Update SOPs to accommodate hybrid trial operations
- Revise risk assessment methods
- Improve monitoring and oversight processes
- Strengthen vendor management practices
Long-term strategic considerations
The feedback shows that Annex 2 is not just tactical advice. It represents a big change in how we think about clinical research. Organizations that adapt early are likely to enjoy a competitive edge.
Key areas for strategic planning:
- Trial design methodology evolution
- Patient engagement strategy development
- Technology partnership evaluation
- Regulatory relationship management
What does this mean for different stakeholders?
For Pharmaceutical companies
Big pharmaceutical companies are working to apply Annex 2 principles to their different products and global operations. The feedback indicates that achieving success hinges on both investing in technology and fostering a cultural shift.
Key success factors identified:
- A strong commitment from executive leadership to embrace new strategies
- Collaboration across clinical, regulatory, and tech teams
- Cultivating a patient-focused culture
- Enhancing regulatory intelligence capabilities
For Biotechnology companies
Smaller biotech companies can benefit from using Annex 2. Traditional clinical trials often favor larger companies with more funding. However, new methods could make things fairer for everyone.
Opportunities for biotechs:
- Lower site management costs
- Quicker patient recruitment via digital channels
- Fewer geographic barriers for participation
- Streamlined data collection and management
For Contract Research Organizations
CROs face both opportunities and challenges with the rollout of Annex 2. Traditional service models might become outdated. However, new services are likely to emerge.
CRO adaptation strategies:
- Developing and integrating technology platforms
- Gaining specialized expertise in managing decentralized trials
- Offering patient engagement and support services
- Providing regulatory consulting for complex trial designs
For Investigators and Sites
Individual investigators and research sites are looking at significant shifts in their roles and responsibilities. The feedback shows a range of reactions to these changes.
Investigator concerns addressed:
- Training and skill requirements for new technologies
- Liability and oversight responsibilities in decentralized environments
- Communication and collaboration protocols
- Implications for revenue models in traditional site operations
The patient perspective
One of the most important parts of the comment overview is the input from patients and patient advocacy groups. Their viewpoints often stand in stark contrast to those of industry stakeholders.
Accessibility and inclusion
Patients have consistently raised concerns about accessibility and inclusion. While decentralized trials can help lower participation barriers, they can also introduce new challenges.
Here are the patient priorities that were highlighted.
- Clear and easy-to-understand communication about trial procedures
- Technical support for using digital platforms
- Flexibility in how and when data is collected
- Respect for privacy and cultural preferences
Burden vs. Benefit Tradeoffs
Patients recognize that some level of inconvenience is a part of clinical trials. However, they want sponsors to thoughtfully weigh the tradeoffs between burden and benefit, particularly in pragmatic trial designs.
Future directions and implications
The comment overview provides a roadmap for future regulatory development. Several trends emerge that will likely influence subsequent guidance documents.
Artificial Intelligence integration
AI applications in clinical trials received significant attention in the comments. While current guidance addresses AI peripherally, future versions will likely provide more detailed guidance.
AI applications discussed:
- Patient recruitment and matching algorithms
- Real-time safety monitoring and alerting
- Data quality assessment and anomaly detection
- Predictive modeling for trial outcome optimization
Regulatory science methodology
The comments suggest that regulatory science itself needs to evolve to evaluate evidence from modern trial designs effectively. Traditional statistical methods may not adequately address real-world data complexities.
International harmonization evolution
While ICH promotes harmonization, the comments reveal that regional differences in implementation may be inevitable and potentially beneficial. Future guidance may acknowledge and accommodate these differences more explicitly.
Practical next steps for implementation
Organizations shouldn’t hold off on planning for implementation until the final Annex 2 is published. The themes in the comments provide plenty of guidance for getting started with initial planning activities.
Assessment and Gap Analysis
Technology Infrastructure
- Take a close look at your current clinical data management systems.
- Check how well they can integrate with external data sources.
- Review your cybersecurity and privacy protection measures.
- Pinpoint any needs for system upgrades or replacements.
Process and procedure review:
- Audit your existing SOPs to ensure they align with Annex 2.
- Identify any gaps in your processes for managing decentralized trials.
- Review your quality assurance procedures in digital environments.
- Assess whether your training programs are adequate for the new requirements.
Organizational readiness
- Evaluate your staff’s competencies for modern trial designs.
- Assess your organization’s cultural readiness for patient-centric approaches.
- Review how well you manage vendors.
- Identify what’s needed for effective change management.
Pilot program development
Many comments recommended using pilot programs to implement Annex 2. This approach allows organizations to gain valuable experience. It also helps in managing risks.
Considerations for pilot programs:
- Start with lower-risk trial designs and patient populations.
- Focus on specific elements of Annex 2 instead of trying to implement everything at once.
- Set clear success metrics and evaluation criteria.
- Plan for ongoing improvements based on what you learn.
Stakeholder engagement
Successful Annex 2 implementation requires engagement with multiple stakeholder groups. The comments emphasize the importance of early and ongoing communication.
Key stakeholder groups:
- Regulatory agencies (for guidance interpretation)
- Technology vendors (for capability development)
- Patient advocacy groups (for design input)
- Investigator networks (for feasibility assessment)
Conclusion: embracing the future of clinical research
The EMA’s 47-page comment overview is not just a regulatory document. It shows us an industry that is changing. Clinical trials are shifting towards being more patient-focused, tech-savvy, and accessible on a global scale. However, with these advancements come new complexities and hurdles to overcome.
The feedback indicates that stakeholders generally support Annex 2. However, they recognize the challenges that lie ahead. Achieving success will demand thoughtful planning, investment in technology, and a shift in organizational culture.
Organizations that use a strategic approach to Annex 2 are likely to gain a competitive edge. This can help them in patient recruitment, operational efficiency, and regulatory acceptance. On the flip side, those who resist change may find themselves falling behind in a rapidly evolving market.
The comments show that the future of clinical research is not just about new technologies. It is also about changing how we create clinical evidence at a basic level. It’s an exciting but daunting prospect, and there’s no denying that this is the path we’re taking.
As we prepare for the final release of Annex 2 in 2025, this summary of comments will be useful for planning. The industry has made its voice heard, and the message is clear: we’re ready for change, but we want to ensure we do it right.
What do you think about the changes to ICH E6(R3) Annex 2? Have you started planning for its use in your organization? How are you updating your Good Clinical Practice training programs to reflect these changes? We want to hear about your experiences and challenges. Also, please subscribe to our newsletter for the latest updates and insights from the industry.
